Publication | Closed Access

Residual normal stem cells can be detected in newly diagnosed chronic myeloid leukemia patients by a new flow cytometric approach and predict for optimal response to imatinib

Hematological MalignancyOncologyMedicineMixed-phenotype Acute LeukemiaOptimal ResponseHematologyMyeloid NeoplasiaPathologyMalignant Blood DisorderStem Cell ResearchCytometryCell BiologyStem CellsCell TransplantationHealth Sciences